PHK
KNTE

Point72 Hong Kong’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Point72 Hong Kong’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-248
Closed -$3K – 1810
2022
Q3 		$3K Buy
+248
New +$3.25K ﹤0.01% 1839
2021
Q4 		– Sell
-1,862
Closed -$43K – 2519
2021
Q3 		$43K Buy
+1,862
New +$40.5K ﹤0.01% 1558
2021
Q1 		– Sell
-5,463
Closed -$217K – 2303
2020
Q4 		$217K Buy
+5,463
New +$219K 0.01% 915

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Point72 Hong Kong's KNTE Position: Q4 2022 in Review

Point72 Hong Kong sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q4 2022, closing a stake of 248 shares — an estimated $3K sold.

Point72 Hong Kong first reported a position in KNTE in Q4 2020 and held it in 3 quarters. The position peaked at $217K in Q4 2020. 79 funds tracked by Wall St. Rank hold KNTE as of Q4 2022.

  • Point72 Hong Kong reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 248 Kinnate Biopharma Inc. Common Stock shares in Q4 2022, an estimated $3K.
  • Point72 Hong Kong first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • Point72 Hong Kong's Kinnate Biopharma Inc. Common Stock position peaked at $217K in Q4 2020.
  • 79 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q4 2022.

Based on Point72 Hong Kong's 13F filing for Q4 2022, filed 14 Feb 2023.